Castle Biosciences Net Tangible Assets

Castle Biosciences (CSTL) currently reports a net tangible assets of $470M as of June 2026. That compares with $460M in the prior-year period — up 3.2% year over year. Use the charts on this page to explore Castle Biosciences's net tangible assets history and peer comparisons.

Castle Biosciences's net tangible assets increased from $460M to $470M — a 3.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Castle Biosciences reported $470M in net tangible assets as of June 2026. That compares with $460M in the prior-year period — up 3.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $470M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Castle Biosciences, and consider following CSTL for alerts when major investors trade the stock.

Castle Biosciences is classified in the Healthcare sector. On net tangible assets, it currently shows $470M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CSTL with unrelated industries.